Join MySLAS Social

Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals

Read this Article

Terry R. Van Vleet, Ph.D., D.A.B.T.
AbbVie Inc.
N. Chicago, IL
USA

 

Terry R. Van Vleet received a bachelor’s degree in zoology with a minor in chemistry from Weber State University (Ogden, UT, USA) and a doctorate in toxicology studying mechanisms of carcinogenesis and metabolic activation of carcinogens at Utah State University (Ogden, UT, USA). His postdoctoral training was at the Medical University of South Carolina (Charleston, SC, USA), studying mechanisms of renal toxicity with an emphasis in mechanisms of mitochondrial dysfunction. Prior to joining Abbvie, Van Vleet worked at Bristol-Myers Squibb for 11 years in positions of increasing importance culminating as the head of the Molecular and In Vitro Toxicology Group. He has been working in investigative toxicology and pathology (preclinical safety) at AbbVie for the last four years as the head of Molecular and Computational Toxicology.

Websites
LinkedIn


SLAS publishes two PubMed:MEDLINE-indexed journals and accepts manuscripts on an ongoing basis from members and non-members.  > READ MORE

December 20, 2018